Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium Tc-99m epratuzumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium Tc-99m epratuzumab is a radiolabeled monoclonal antibody that combines the humanized anti-CD22 antibody, epratuzumab, with the gamma-emitting radioisotope technetium Tc-99m. This agent targets CD22, a cell surface glycoprotein expressed on B-lymphocyte lineage cells and many malignant B-cells. By binding to CD22, it delivers the radioactive payload directly to these cells for diagnostic imaging or potential therapeutic purposes in oncology, particularly for diseases involving abnormal B-cell proliferation such as non-Hodgkin lymphoma[1][3][8]. The mechanism of action involves specific targeting of CD22-positive cells and delivery of gamma radiation for imaging.
- Other names
- technetium tc 99m epratuzumab
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on Technetium Tc-99m epratuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Technetium Tc-99m epratuzumab.